Biodegradable hollow mesoporous organosilica nanotheranostics (HMON) for multi-mode imaging and mild photo-therapeutic-induced mitochondrial fusion on gastric cancer

CURRENT STATUS: UNDER REVIEW

Weihong Guo
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Zhian Chen
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Jiajia Chen
National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510000, China

Xiaoli Feng
Guangdong Provincial Stomatology Hospital, Southern Medical University, Guangzhou 510000, China

Yang Yang
National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510000, China

Huilin Huang
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Yanrui Liang
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Guodong Shen
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Yu Liang
Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Chao Peng
Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Yanbing Li
National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510000, China

Guoxin Li
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Wenhua Huang
Chukwuemeka Odumegwu Ojukwu University Faculty of Basic Medical Sciences

Bingxia Zhao
Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University

Yanfeng Hu
Department of general surgery, Nanfang Hospital, Southern Medical University, Guangzhou

banby@smu.edu.cn Corresponding Author
ORCiD: https://orcid.org/0000-0001-5608-3587

DOI: 10.21203/rs.3.rs-22585/v1

SUBJECT AREAS
Nanoscience

KEYWORDS
Hollow mesoporous organosilica nanoparticles (HMON), Photo-thermal therapy (PTT), Photo-dynamic therapy (PDT), Multi-modal imaging, Mitochondrial fusion
Abstract
CuS-modified hollow mesoporous organosilica nanoparticles (HMON@CuS) have been preferred as non-invasive treatment for cancer, as near infrared (NIR)-induced photo-thermal effect (PTT) and/or photo-dynamic effect (PDT) could increase cancer cells’ apoptosis. However, the certain role of HMON@CuS-produced-PTT&PDT inducing gastric cancer (GC) cells’ mitochondrial fusion, remained unclear. Moreover, theranostic efficiency of HMON@CuS might be well improved by applying multi-modal imaging which could offer an optimal therapeutic region and time window. Herein, new nanotheranostics agents were reported by Gd doped HMON decorated by CuS nanocrystals (called HMON@CuS/Gd), which exhibited appropriate size distribution, good biocompatibility, L-Glutathione (GSH) responsive degradable properties, high photo-thermal conversion efficiency (82.4%) and a simultaneous reactive oxygen species (ROS) generation effect. Meanwhile, HMON@CuS/Gd could efficiently enter GC cells, induce combined PDT and mild PTT (43-45 °C) under mild NIR power density (0.8W/cm²). Surprisingly, it was found that PTT might not be the key factor of cell apoptosis, as ROS induced by PDT seems playing a more essential role. The NIR-induced ROS could attack mitochondrial membrane potentials (MTPs), then promote mitochondrial reactive oxygen species (mitoROS) production. Meanwhile, mitochondrial fusion dramatically changed the expression of anti-apoptotic protein (Bcl-2) and pro-apoptotic protein (Bax). Since that, mitochondrial permeability transition pore (mPTP) was opened, followed by inducing more cytochrome c (Cyto C) releasing from mitochondria into cytosol, and finally activated caspase-9/caspase-3-depended cell apoptosis pathway. Our in vivo data also showed that HMON@CuS/Gd exhibited good fluorescence (FL) imaging (wrapping fluorescent agent), enhanced T1 imaging under magnetic resonance imaging (MRI) and infrared thermal (IRT) imaging capacities. Guided by FL/MRI/ IRT trimodal imaging, HMON@CuS/Gd could selectively cause mild photo-therapy at cancer region, efficiently inhibit the growth of GC cells without evident systemic toxicity in vivo. Taken together, HMON@CuS/Gd could serve as a promising multifunctional nanotheranostic platform and as a cancer photo-therapy agent through inducing mitochondrial fusion on GC.

Background
Gastric cancer (GC) is one of the most common malignant tumors and its mortality rate ranks third worldwide. Despite of the great progress of traditional chemotherapy and molecular target therapy, the prognosis of GC is still relatively poor, especially in China\textsuperscript{[1, 2]}. Considering the limitations of current diagnosis and therapy methods, there is a pressing need to identify novel potential strategies to offer new, improved diagnosis and therapy methods for GC.

Recently, reactive oxygen species (ROS) have attracted more attention due to its regulation in cancer development. Moderate levels of ROS could promote tumor progression by inducing DNA mutations, genomic instabilities or acting as signaling molecules that accelerate cancer cell proliferation and metastasis\textsuperscript{[3]}. In contrast, excessive levels of ROS might enhance cellular oxidative stress, cause DNA/proteins/lipids damage, and lead to apoptotic cell death\textsuperscript{[4]}. As the main organelle for ROS production, mitochondria are often the victim of exogenous elevated ROS exposure with deadly consequences, such as oxidative damage of mitochondrial DNA (mitoDNA), oxidative respiratory chain and mitochondrial membrane permeability\textsuperscript{[5, 6]}. To our knowledge, mitochondria play a significant role in numerous biological processes, including the initiation of cell death, cellular energy generation and metabolic integration\textsuperscript{[7, 8]}. Accumulating evidence has identified that mitochondrial dysfunction was always accompanied with interfered oxidative respiratory chain, which might reduce intracellular ATP levels and fail to produce enough energy for tumor growth\textsuperscript{[9, 10]}. Meanwhile, mitochondrial damage induces cytochrome C (Cyto C) leakage from mitochondria into cytosol, while high levels of Cyto C subsequently activate caspase-depended apoptosis pathway \textsuperscript{[11, 12]}. Therefore, boosting ROS could be a crucial way for activating mitochondria-depended apoptosis pathway, while precise ROS-generation at GC region is still a big problem.

Near infrared light (NIR)-based photo-therapy (PT) has been preferred for tumors targeting treatment, due to the advantages of minimal harm to normal tissues, non-invasiveness, and efficient therapeutic ability\textsuperscript{[13, 14]}. Emerging studies have also identified that with the assistance of NIR, photosensitizers could increase the production of ROS to cause mitochondria-depended cancer cell death\textsuperscript{[15-17]}. To
some extent, the combination of photo-thermal therapy (PTT) and photo-dynamic therapy (PDT) could achieve much better therapeutic efficiency, as hyperthermia has been reported with the ability to elevate the level of oxygen in the tumor due to the increase of blood flow\textsuperscript{[18, 19]}, thus overcoming the hypoxia-associated resistance for PDT. Several hollow mesoporous organosilica nanoparticles (HMON) carrying CuS, ICG or 7AAG, had been reported with ROS generation ability under single laser irradiation with the intrinsic photo-thermal property, which could be used for PDT&PTT synergistic therapy, utilizing the good dispersion and high drug-loading capability of HMON and the photothermal ability of HMON \textsuperscript{[20, 21]}.

However, the lasers employed for the PTT&PDT treatments are usually different, thus the time interval between different modes will affect the synergistic efficacy\textsuperscript{[22]}. Meanwhile, since PTT-treated cells readily acquire tolerance to heat stress, a relatively high temperature (>50 °C) was required to achieve the desired therapeutic effect, which would inevitably cause damage to normal organs near the tumor\textsuperscript{[23, 24]}. Therefore, there is still a great need to provide the synchronous implementation of PDT&PTT utilizing a single laser irradiation at mild-temperatures (43-45 °C), while targeted delivery of a photosensitizers to the intended area holds potential to pinpoint the site of therapeutic efficacy. Furthermore, the certain role of PTT&PDT influencing GC cells’ apoptosis at mild temperature also needs further exploration.

Herein, HMON nanoparticles were decorated with CuS nanocrystals (HMON@CuS NPs) via \textit{in situ} growth, following the protocol of our previous work where CuS nanocrystals were \textit{in situ} grown onto the surface of hollow mesoporous nanospheres\textsuperscript{[19]}. The designed nanoparticle performed well PDT and PTT conversion efficiency and better biocompatibility. Furthermore, Gd was doped into the NPs and NIR fluorescent imaging agent was loaded into the hollow structure, good fluorescence (FL) imaging (wrapping fluorescent agent), enhanced T1 imaging under magnetic resonance imaging (MRI) and infrared thermal (IRT) trimodal imaging could therefore be achieved to guide photo-therapy\textsuperscript{[25]}. After treated with HMON@CuS/Gd under NIR irradiation, \textit{in vitro} and \textit{in vivo} GC proliferation abilities were evaluated. Moreover, to fully elucidate whether ROS-mediated mitochondrial apoptosis pathway
contributed to the anti-tumor effects induced by HMON@CuS/Gd, we detected the changes of ROS levels and the biological function of mitochondria, including mitochondrial transmembrane potentials (MTPs), mitochondrial ROS (mitoROS) and mPTP produced levels, along with the expression levels of Cyto C and apoptosis-related proteins. Above all, our well designed HMON@CuS/Gd might present a promising approach for the imaging-guided treatment of gastric cancer (Scheme 1 - provided as Figure 8).

Materials And Methods

2.1 Materials

Cetyltrimethylammonium chloride solution (CTAC), triethanolamine (TEA), tetraethoxysilane (TEOS), sodium citrate (3-mercaptopropyl)-trimethoxysilane (MPTES), concentrated HCl (37%), ammonia aqueous solution (NH₃·H₂O, 25wt%), bis[3-(triethoxysilyl)propyl]tetrasulfide (BTES), sodium sulfide nonahydrate (Na₂S·9H₂O), copper chloridedihydrate (CuCl₂·2H₂O), Gadolinium chloride hexahydrate (GdCl₃·6H₂O) were purchased from Sigma-Aldrich (MO, USA). The C18PMH-mPEG was purchased from laysan Bio Inc. (AL, USA). The PBS, DMEN medium, Fetal bovine serum (FBS) and 0.05% trypsin-EDTA were obtained from Gibco Laboratories (NY, USA). The GES-1 and HGC-27 cell line were acquired from American Type Culture Collection (ATCC).

2.2 Synthesis of HMON

In this study, we applied an ammonia-assisted selective etching strategy to construct the hollow structure of HMON nanocarriers. Briefly, 2.1 ml of CTAC solution and 50 ul TEA solution were added into 20 ml deionized water (ddH₂O), followed by stirred at 95°C, and then 1 ml of TEOS were dropwised into the mix solution. 1 hour later, a mixture of BTES (1 ml) and TEOS (1 ml) were dropwised and reacted for another 4 hours to form MSN@MON products. The MSN@MON products were washed with ethanol for three times. Subsequently, the MSN@MON products were suspended with 30 ml ddH₂O containing 8.4 ml HCl solution (37%) and stirred at 80°C for 12h to remove the unreacted CTAC, then washed with ethanol and repeated the reaction once again. After that, a mixture of 20 ml of ddH₂O and 13.5 ml ammonia solution were added and reacted at 60°C for another
3 hours. Finally, the HMON products were obtained after centrifugation and washing with ddH₂O for several times.

2.3 Synthesis of HMON@CuS/Gd

Firstly, 30 mg of HMON products were suspended with 40 ml ethanol solution. Subsequently, 15 mg of CuCl₂·6H₂O were added and reacted for another 6 hours. After washing with ethanol for several times, 30 mg of Na₂S were added and stirred overnight at room temperature. Following that, 15 mg of GdCl₃·6H₂O were added into the obtained solution for 1 hour, washed with ethanol for several times, and finally HMON@CuS/Gd were collected after centrifugation. Furthermore, in order to the water-solubility and biocompatibilities, HMON@CuS/Gd were stirred with 15 mg of C18PMH-mPEG[26] and kept stirring for 1 hour before blow-drying of the chloroform. Finally, the PEG-modified HMON@CuS/Gd nanospheres were collected by centrifugation and washed with ddH₂O for several times.

2.4 Characterization of HMON@CuS/Gd

The surface morphology and elemental mapping images of HMON@CuS/Gd NPs were captured by JEOL JEM-2100F TEM. In addition, zeta potentials and hydrodynamic diameters of various samples were detected using a Zetasizer Nano ZS (Malvern). In order to detect the photothermal effect, different concentrations of HMON@CuS, HMON@Gd or HMON@CuS/Gd NPs in PBS solutions (200 μl) were irradiated with an 808 nm NIR laser (0.8W/cm², 5 mins). The real-time temperatures of the solutions were recorded using a FLIR E50 camera system.

2.5 Calculation of Photo-thermal Conversion Efficiency of HMON@CuS/Gd at 808 nm.

The photothermal conversion efficiency of HMON@CuS/Gd was calculated by the following equation:

\[
\eta = \frac{hS(T_{\text{max}} - T_{\text{max,water}})}{I(1 - 10^{-4808})} \times 100\%
\]

Where \( h \) is the heat transfer coefficient, \( S \) is the surface area of the container, \( T_{\text{max}} \) is the maximum equilibrium temperature for HMON@CuS/Gd NPs solution, while \( T_{\text{max,water}} \) is the maximum equilibrium temperature for water.
temperature for water. In addition, I refer to the laser power (0.8W/cm\(^2\)), and \(A_{808}\) is the absorbance of the HMON@CuS/Gd NPs at 808 nm.

\[
hS = \frac{m_D \times C_D}{\tau_S}
\]

Where \(m_D\) and \(C_D\) refers to the weight of water and the heat capacity of water respectively. In addition, \(\tau_S\) is time constant of the sample.

\[
t = -\tau_S \times \ln \theta, \quad \theta = \frac{T_{amb} - T}{T_{amb} - T_{max}}
\]

Where \(T_{amb}\) is surrounding ambient temperature. Therefore, the \(\tau_S\) can be calculated using the linear regression curve between cooling stage and negative natural logarithm of driving force temperature of HMON@CuS/Gd NPs.

2.6 Detection of singlet oxygen on solutions

After treated with or without NIR laser irradiation, the Singlet Oxygen Sensor Green reagent (Life Technologies, Carlsbad, CA, USA) was used to detect the production of singlet oxygen on the solutions contained HMON@CuS, HMON@Gd and HMON@CuS/Gd NPs using a Jasco (Easton, MD, USA) FP-6200 spectrofluorometer.

2.7 Biocompatibilities of HMON@CuS/Gd

To address biocompatibility issues, normal GES-1 gastric cell lines were treated with PEG-modified or non-PEG-modified HMON@CuS/Gd solutions for 24h. Then, cell viability was quantified with CCK-8 assay (Dojindo, Tokyo, Japan) and a microplate reader. In order to evaluate immunotoxicity, the mouse macrophage (RAW264.7) cells were seeded into CLSM dishes and treated with HMON@CuS/Gd for 24h. Subsequently, treated cells were washed, fixed with 4% paraformaldehyde, treated with 1% bovine serum albumin (BSA), incubated with 0.1% Triton X-100, and finally stained with rhodamine-phalloidin (Abcam, Cambridge, UK) and with 4’,6-diamidino-2-phenylindole (DAPI; Abcam, Cambridge, UK). Finally, confocal laser scanning microscope (CLSM; Olympus, Tokyo, Japan) was used to observe
and photograph stain cells.

2.8 Cell uptake of HMON@CuS/Gd

In order to access the intracellular uptake efficiency, the HGC-27 cells were planted in CLSM dishes, and then treated with FITC-labeled HMON@CuS/Gd, which were constructed as the followings: Briefly, 20 mg of HMON@CuS/Gd products were suspended with 20 ml ddH$_2$O, and then 1 mg fluorescein isothiocyanate (FITC) were added and kept stirring for 8 hours. After concentration and washing with ddH$_2$O, the FITC-labeled HMON@CuS/Gd were constructed. After incubation for 1, 2 and 4 hours, the cells were washed with PBS and collected. Following that, cells were directly analyzed by flow cytometry assay. For immunofluorescence imaging, treated cells were fixed with 4% paraformaldehyde, and stained with DAPI. Finally, The CLSM dishes were observed and imaged with CLSM (Olympus).

2.9 In vitro photo-therapeutic effect of HMON@CuS/Gd

HGC-27 cells were pretreated with HMON@CuS/Gd, with or without an 808 nm laser at a power density of 0.8 W/cm$^2$ for 5 mins respectively. 24 hours later, the treated cells were collected and incubated with CCK-8 kit for viabilities detection, with Annexin V-FITC/PI Kit (KeyGEN, Nanjing, China) for apoptosis detection and EDU testing kit (Ruibo, Guangzhou, China) for cell proliferation ability detection. Furthermore, in order to evaluate mitochondrial function, the treated cells were also harvested and detected with JC-1 Kit (Keygen), mitoROS kit (AAT Bioquest, Wuhan, China), ROS Kit (Keygen), mPTP kit (BestBio, Shanghai, China) follow the manual instructions.

2.10 In vivo multi-modal imaging behaviors of HMON@CuS/Gd

In order to evaluate the multi-modal imaging behaviors of HMON@CuS/Gd, HGC-27 cells were harvested and suspended with appropriate amount of PBS, and then 50 μl of suspension was injected into the right flank of mice to construct tumor-bearing nude mice. Then, when tumor volume exceeded 500 mm$^3$, the model nude mice were randomly divided into different groups. For fluorescence images, the tumor-bearing mice were injected with DIR labeled HMON@CuS/Gd via tail vein injections, while DIR-labeled HMON@CuS/Gd were firstly constructed using similar methods.
shown in 2.8. At the time point of 6 h, 12 h and 24 h after injection, the fluorescence images of whole body and their major organs were all detected by fluorescence imaging system (Digital Fprcision Medicine Company, Beijing, China). For IRT images, the tumor-bearing mice were anesthetized before and after injecting with HMON@CuS/Gd, then thermographic images were captured by a FLIR E50 camera at the present of NIR laser irradiation. For MRI images, single HMON@CuS/Gd solutions, and tumor-bearing mice were anesthetized before and after injecting with HMON@CuS/Gd, then MRI images were captured through a 3.0 T MAGNETOM Skyra MRI scanner (Phihips, Amsterdam, Netherlands) using T1-weighted sequence (TR=450.0ms, TE =15.3ms, thickness =2mm).

All animal procedures were approved by Nanfang Hospital of Southern Medical University (Certification No. L2017243), which were approved by the Medical Ethics Committee of Nanfang Hospital of Southern Medical University. All procedures of the investigation were carried out following the rules of the Declaration of Helsinki of 2008 (https://www.wma.net/what-we-do/medical-ethics/declarationofhelsinki/), revised in 2008. All of the animal experiments in this study were approved by the Institutional Animal Care and Use Committee of Nanfang Hospital of Southern Medical University.

2.11 In vivo photo-therapeutic effect of HMON@CuS/Gd

In order to clarify the photo-therapeutic effect of HMON@CuS/Gd, tumor-bearing mice were randomly divided into four groups, which were treated with saline and HMON@CuS/Gd, with or without irradiation of NIR (0.8 W/cm², 8 mins). The body weight and tumor volume were recorded every three days for 14 days. At the 14th day, the mice were euthanized, and then their tumor tissues were excised and fixed in 4% formalin for immunohistochemistry (IHC; Tunel, Abcam, USA) and H&E staining.

2.12 Statistical analysis

Data are showed as mean ± standard deviation (SD). Quantitative analysis of the immunofluorescence intensity, western-blotting bands and IHC stained area by aniline was conducted using the Image J program (National Institutes of Health, Bethesda, MD). The differences between the mean values were analyzed using SPSS21.0 (International Business Machines Corporation, Armonk, NY) and one-way
ANOVO statistical approach. Results were considered statistically significant when $P<0.05$. All experiments were repeated at least 3 times.

**Results And Discussion**

### 3.1 Preparation, characterization and in vitro photo-thermal effect of HMON@CuS/Gd

HMON were synthesized via a mild selective etching progress. In brief, mesoporous organosilica nanospheres with large pore were firstly synthesized by the dual hydrolysis and condensation of BTES and TEOS under the catalyzation of TEA, while CTAC was used for pore forming. As the dominant $-\text{Si-O-}$ bonds were weaker than the $-\text{Si-C-}$ bonds within the outer sites, the inner part of the mesoporous organosilica nanospheres were then etched using diluted ammonia to form the hollow mesoporous structure, bridged by $-\text{S-S-}$ bonds$^{[21]}$. Though it has been reported that CuS NPs could be conjugated onto the surface of HMON through thiol groups, it required respective synthesis of HMON and CuS following the conjugation progress. The multi-steps protocol might be simplified as it has also been reported that Si-O- groups on the surface of the HMON have the potential to bond with metal ions (such as Fe$^{3+}$, Au$^+$, etc.) without the need of additional molecular chelator$^{[27, 28]}$. In our previous work, CuS nanocrystals were *in situ* grown onto the surface of hollow mesoporous TaOx nanospheres without the help of thiol groups$^{[19]}$. Herein, CuS nanocrystals were in situ grown onto the surface of the HMON similarly. Briefly, Cu$^{2+}$ ions were added directly into the HMON solution and adsorbed onto the HMON, following the addition of Na$_2$S to achieve the *in situ* nucleation and growth of CuS nanocrystals. Finally, the HMON@CuS/Gd NPs were constructed with the addition of GdCl$_3$·6H$_2$O.

Then, the element mapping of HMON@CuS/Gd NPs showed that the Cu$^{2+}$ and Gd$^{2+}$ ions were successfully jointed together onto the surface of HMON (Figure 1A). It is noticeable that the etching degree by diluted ammonia has great influence on the ability of the HMON to absorb Cu$^{2+}$ ions. HMON with excessive etching leading to the poor conjugation with Cu$^{2+}$ and Gd$^{3+}$ ions due to the depletion of $-\text{Si-O-}$ bonds. Eventually, C18PMH-mPEG was applied to improve the stability and dispersity of the HMON@CuS/Gd nanospheres.

In addition, the diameters of HMON was $115.5\pm1.46$ nm, while CuS or/and Gd$^{2+}$ loading led to a slight
increase in the size of the HMON@CuS (116.7±1.51 nm) and HMON@CuS/Gd (117.1±1.71 nm), and all of them exhibited unimodal size distribution. Meanwhile, the data also indicated that both of HMON@CuS and HMON@CuS/Gd NPs possessed negative net charge, which could help to improve their circulation stability (Supplementary files, Figure S1). Compared to these PEG modified HMON NPs, HMON-based materials without PEG modification also showed negative net charge, and slight minor diameters. However, the diameters’ SD value in HMON (108.2±4.54 nm), HMON@CuS (109.4±3.41 nm) and HMON@CuS/Gd (110.1±4.15 nm) NPs were larger than those in PEG-modified HMON NPs, indicating that C18PMH-mPEG could improve their stability (Supplementary files, Figure S2). Consequently, PEG modified HMON NPs were chosen for further experiments in our research. Due to the presence of the disulfide bonds in the framework of HMON, HMON@CuS/Gd exhibited time-dependent biodegradable behavior in the glutathione (GSH) solutions (Figure 1B), indicating that HMON@CuS/Gd NPs could be bio-degradable and eliminated through feces and urine, thus the drug accumulation leaded toxicity could be avoided.

It could also be expected that the as-prepared NPs possess the potential to be applied as MR imaging contrast agent due to the addition of Gd\[^{29, 30}\]. In vitro experiment demonstrated that T1 signal intensity was enhanced with the increasing concentration of HMON@CuS/Gd solutions. As calculated, significant increase of SNR (signal to noise ratio) could also be observed, indicating the outstanding potential for MR imaging (Figure 1C&D). Besides the MRI imaging properties, we further investigate the photo-thermal conversion efficiency of HMON@CuS/Gd NPs, we monitored the temperature changes under laser irradiation in vitro using an infrared thermal imaging camera. After NIR laser irradiation (0.8 W/cm\(^2\)) for 5 mins, dramatical temperature increase was observed in HMON@CuS/Gd and HMON@CuS groups, while no obvious temperature change was shown in PBS or HMON@Gd groups with the same laser irradiation. The maximum increased temperature (ΔT\(_{max}\)) of HMON@CuS/Gd and HMON@CuS groups (1000µg/mL) ∼38 °C, whereas the ΔT\(_{max}\) of other HMON@CuS/Gd and HMON@CuS groups (100µg/mL, 50µg/mL and 12.5µg/mL) increased to ∼16.0 °C, ∼8.0 °C and ∼6.0 °C respectively (Figure 1E&F; Supplementary files, Figure S3. It is worth pointing
that HMON@CuS/Gd and HMON@CuS NPs showed good temperature response under the NIR laser irradiation conditions, which demonstrating that the photo-thermal conversion efficiency was contributed to the presence of CuS. Moreover, HMON@CuS/Gd NPs showed an excellently stable photo-thermal performance, as the heat-cool curve of HMON@CuS/Gd NPs had no significant difference within five cycles of NIR laser irradiation (Supplementary files, Figure S4). According to the linear regression curve between the cooling stage and negative natural logarithm of driving force temperature of HMON@CuS/Gd, the photo-thermal conversion efficiency of HMON@CuS/Gd NPs was calculated to be 82.4% (Figure 1G). In addition, to determine whether HMON@CuS/Gd NPs could produce ROS under NIR laser irradiation, a singlet oxygen sensor was applied to detect the ROS production levels. As shown in Figure 1H, HMON@CuS/Gd NPs exhibited concentration-dependent production of ROS in deionized water, indicating that HMON@CuS/Gd NPs possessed excellent photodynamic ability. Moreover, HMON@CuS NPs showed similar ROS generation ability in the presence of NIR, while no excessive singlet oxygen was observed in HMON@Gd NPs, with or without NIR treatment (Supplementary files, Figure S5), which demonstrating that the ROS generation capacity of HMON@CuS/Gd NPs were contributed to the presence of CuS. Therefore, HMON@CuS/Gd would be promising PTT, PDT and functional imaging NPs for the treatment of GC.

### 3.2 In vitro photo-therapeutic effect of HMON@CuS/Gd nanoparticles in GC cells

Firstly, we tested the in vitro photo-therapeutic effects of HMON@CuS/Gd on HGC-27 GC cells. Briefly, HGC-27 cells were first incubated with HMON@CuS/Gd NPs at different concentrations for 4 h and then were irradiated with an 808 nm laser at a power density of 0.8 W/cm² for 5 mins. After 24 h, CCK-8 assay was applied to evaluate the antitumor therapeutic efficacies of HMON@CuS/Gd. As shown in Figure 2A, free HMON@CuS/Gd and single NIR laser treatment did not induce significant changes in cell death, since the half maximal inhibitory concentration (IC50) of HMON@CuS/Gd was as high as 570.01µg/ml. Furthermore, dramatical decreased cell viabilities were observed in HMON@CuS/Gd plus laser irradiation group (IC50=50.51µg/ml), indicating that HMON@CuS/Gd exhibited an effective photo-therapy effect with NIR irradiation. In the other hand, HMON@CuS exhibited similar anti-tumor effect with NIR irradiation, compared to HMON@CuS/Gd plus NIR
irradiation group, indicating that photo-therapy effect was contributed to the addition of CuS, while Gd showed no cell toxicity (Supplementary files, Figure S6). Consistently, LDH assay revealed that HMON@CuS/Gd plus laser irradiation induced higher levels of LDH leakage than blank group, while HMON@CuS/Gd only and single NIR laser did not induce any LDH changes (Figure 2B). These results suggested that HMON@CuS/Gd could provide a promising killing effect to gastric cancer cells, with the irradiation of NIR.

As it has been reported, several Cu-based NPs had been applied for PDT&PTT synergistic therapy. Though HMON@CuS NPs have been applied for tumor-specific delivery of O2-saturated perfluoropentane (PFP) to achieve photo-thermal induced bubble-enhanced oxygen-sensitized radiotherapy, the therapeutic effect of the HMON@CuS alone, especially the role of HMON@CuS-induced ROS, has not been discussed. Consequently, it is wondered whether the therapeutic effect was achieved by PTT ablation alone or PDT also played some certain role in the therapeutic progress.

In order to evaluate the PDT effect, HGC-27 cells were placed on an ice box while being irradiated with NIR light and the temperature was controlled below 10°C to minimize the effect of NIR-induced PTT ablation. To our surprise, significant cell death was still observed in this condition, though not as obvious as HMON@CuS/Gd plus NIR treatment, as IC50 raised to 122.4 µg/ml (Figure 2C). Evident LDH leakage could still be found as shown in Figure 2D.

When referring to PTT effect, clinicians have pointed out that tumor cells might occur apoptosis under 43-45°C, while normal cells are generally tolerant to this temperature condition. In another word, PTT effect refers to generating external 45 °C heating at cancer region, which is supposed to have a direct cytotoxic effect on tumor cells, and enhance the efficacy of chemotherapy and radiotherapy, improve the body's immunity, and thus suppress tumor progression. Coincidentally, it could be observed by the IR camera that when HGC-27 cells were treated with HMON@CuS/Gd (50 µg/ml) plus NIR irradiation (0.8 W/cm², 5mins), the temperature could raise up to around 45 °C at 37°C temperature condition. Consequently, HMON@CuS/Gd with 50 µg/ml concentration were chosen for the following cellular experiments. Simulated 45 °C external temperature condition using a cell
culture incubator was set as control. It could be seen that only slight cell death and LDH leakage were observed in the external heating group comparing with the NIR irradiation group, indicating hyperthermia might not be the key factor (Figure 3C&D). Taken together, it could be concluded that HMON@CuS/Gd could induce combined PDT and PTT effect, while this obvious anti-tumor cell death was mainly contributed to their PDT effect.

To address biocompatibility issues, *in vitro* experiments were performed by incubating HMON@CuS/Gd NPs with normal GES-1 gastric cell lines. The CCK-8 assay revealed viability rates above 85% for GES-1 cells as the concentration ranging from 0-512 µg/mL, while the IC50 of HMON@CuS/Gd was as high as 957 µg/ml to GES-1 cells (Figure 2E). However, when treated with no PEG modified HMON@CuS/Gd NPs, cell viability rates for GES-1 cells showed significant decrease (IC50=312 µg/ml; *Supplementary files, Figure S7*), indicating the addition of PEG could improve their bio-safety, and PEG modified HMON@CuS/Gd were consequently chosen for further experiments in our research. Surprisingly it could be observed that IC50 to GES-1 cells was much higher than HGC-27 GC cells, indicating that the as-prepared HMON@CuS/Gd showed specific toxicity to cancer cell.

Furthermore, HMON@CuS/Gd (50 µg/mL) were also co-incubated with RAW264.7 murine macrophage-like cells. This immunotoxicity experiment revealed that HMON@CuS/Gd treatment did not elicit any inflammatory response at the cellular level (Figure 2F). These results strongly indicated that HMON@CuS/Gd NPs have good *in vitro* biocompatibilities, highlighting their value for clinical translation as drug carriers.

**3.3 In vitro cellular uptake and anti-GC effect of HMON@CuS/Gd nanoparticles**

Cellular uptake of the HMON@CuS/Gd were then investigated by flow cytometry and confocal laser scanning microscopy (CLSM) assays, while FITC were firstly encapsulated into HMON@CuS/Gd NPs. After incubating with HMON@CuS/Gd (50 µg/mL) for 1-4 h, the FITC fluorescence intensities increased significantly as time passed by (Figure 3A&B), indicating the excellent cellular uptake efficiency of HMON@CuS/Gd. Since HMON@CuS/Gd could efficiently enter GC cells, we further detected the apoptosis rates determined by flow cytometry, which demonstrated that HMON@CuS/Gd plus NIR laser irradiation induced 2-fold higher levels of total apoptosis (14%) than blank group (5%), while
free HMON@CuS/Gd and single NIR laser did not induce any apoptotic change (Figure 3C). EdU dye is a kind of thymidine nucleoside analogues, which could specifically insert into DNA molecules of rapid proliferation cells, and higher EdU-positive cell rates usually demonstrate better cell growth abilities. In our research, after conjugated reactions with EdU, we found that HMON@CuS/Gd plus NIR laser irradiation induced 2-fold lower levels of EdU-positive rates (15%) than blank group (40%), while free HMON@CuS/Gd NPs and single NIR laser did not induce any EdU-positive rates change (Figure 3D). These results suggested that HMON@CuS/Gd provided a promising anti-proliferation and promoting apoptotic effects to gastric cancer cells, with the irradiation of NIR.

3.4 Anti-tumor mechanism of photo-therapeutic effect induced by HMON@CuS/Gd

Though excellent anti-tumor effect has been proved, their relevant photo-therapeutic mechanism remained unknown. To examine the cancer-killing mechanism of HMON@CuS/Gd, we incubated HGC-27 cells with HMON@CuS/Gd (50 µg/ml) for 4 h, irradiated with an 808 nm laser (0.8 W/cm², 5 mins), then observed by TEM. Surprisingly, dozens of mitochondria were shown in non-treated HGC-27 cells, while no mitochondria were observed in treated HGC-27 cells (Figure 4A). Meanwhile, it could be proved that mitochondrial membrane potentials (MTPs) of HGC-27 cells was reduced by HMON@CuS/Gd NPs with the assistance of NIR irradiation, further indicating the damage of mitochondria (Figure 4B). Consequently, we assumed that HMON@CuS/Gd induced PTT&PDT probably resulted in mitochondrial fusion to exert its function.

Mitochondria are central organelles for the regulation of cancer cell life and death, to which the damage can directly activate the intrinsic apoptosis pathway. When cells receive certain external stimuli, the mitochondrial electron transport is blocked, MTPs changes, the maintain of mPTP is disrupted and cytochrome c (Cyto c) release, followed by activates caspase-depended apoptosis pathway. Actually, the mitochondrial-dependent damage could be triggered via a range of exogenous and endogenous stimuli, such as oxidative stress, ischemia and DNA damage. As it is well-known, ROS are inevitable products of cell metabolism, while high levels of intracellular ROS could attack mitochondria and cause mitochondrial-damage-dependent apoptosis. Accumulating
studies had proved that NIR-mediated PTT&PDT could induce the outbreak of ROS, following by activating oxidative stress and mediating mitochondrial damage in cancer cells\cite{15, 16, 40}. As it has been demonstrated in the CCK-8 results, HMON@CuS/Gd induced obvious anti-tumor cell death mainly contributed by their PDT effect. In order to clarify the ROS generation, DCFH-DA was applied as biological probe to monitor the intracellular level of ROS\cite{41}. Increasing ROS generation was found to be significantly increased in HMON@CuS/Gd plus NIR treated HGC-27 cells (Figure 4C). To further identify the PDT effect, HGC-27 cells were placed on an ice box while being irradiated with NIR light and the temperature was controlled below 10°C to minimize the effect of NIR-induced photo-thermal ablation. Interestingly, dramatical increase of ROS was still observed in this condition, though not as obvious as HMON@CuS/Gd plus NIR treatment. Meanwhile, our results showed that minor ROS was produced in the external heating group (Supplementary files, Figure S8). Consequently, it could be concluded that HMON@CuS/Gd could induce ROS generation, was also mainly contributed to their PDT effect.

Meanwhile, in order to clarify whether the generated ROS could cause mitochondrial dysfunction, MitoSOX Red was used as an indicator to discern the superoxide in mitochondria through flow cytometry analysis (FACS) in this study.\cite{42} Notably, a sharp increase in red fluorescence (refer to mitochondrial ROS, also called mitoROS) was detected in HMON@CuS/Gd plus NIR group (Figure 4D). Taken together, we assumed that photo-therapeutic effect induced by HMON@CuS/Gd NPs might promote intracellular ROS level and induce mitochondrial dysfunction to some extent. The formation of much more amount of mitoROS species was also discovered, which in turn aggravate the damage of mitochondria and might activate the Caspase-depended apoptosis pathway. To verify whether the Caspase-depended apoptosis pathway was activated, the expression of pro-apoptotic protein (Bax) and anti-apoptotic protein (Bcl-2) was detected. It could be seen that pro-apoptotic protein (Bax) dramatically elevated and anti-apoptotic protein (Bcl-2) decreased (Figure 4E; Supplementary files, Figure S9). As Bax was a pro-apoptotic protein with multiple Bcl-2 homology domains, this alteration could alter permeability of mitochondrial outer membrane (mPTP)\cite{43} (Figure 4F; Supplementary files,
Figure S10). MPTP opening is the primary event of the mitochondrial intrinsic apoptosis pathway, could be referred as sudden mitochondrial permeability transition and loss of inner mitochondrial potential, leading to the increase of cytochrome c (Cyto C) (Figure 4E; Supplementary files, Figure S9). Considering Cyto c release from mitochondria to the cytoplasm has been verified as the most important event in caspase depended mitochondrial mediated apoptosis signal transduction pathway, the expression of apoptotic proteins in treated cells were further detected. From the western blot results, the scale of the expressed well-defined apoptosis protein markers (cleaved caspase-9/caspase-9, cleaved caspase-3/caspase-3) was markedly increased in HMON@CuS/Gd plus NIR group, compared with other three groups (Figure 4G; Supplementary files, Figure S11). Through the involvement of caspase-9, Caspase-3 is subsequently cleaved, which could activate DNA fragmentation, thereby inducing cell apoptosis.\textsuperscript{[44, 45]} Taken together, our research demonstrates that HMON@CuS/Gd NPs plus NIR treatment did induce mitochondrial fusion to trigger GC cells’ caspase-dependent apoptosis pathway.

In order to further confirm whether the mitochondrial-damage-dependent apoptosis pathway contributed by HMON@CuS/Gd plus NIR treatment, N-Acetyl-L-cysteine (NAC, an anti-oxidant containing sulphydryl group) was applied for the rescue experiments.\textsuperscript{[46]} With the addition of NAC, intracellular ROS level in HMON@CuS/Gd plus NIR treated HGC-27 cells was dramatically decreased (Figure 5A). Interestingly, MTPs, mitoROS and mPTP in treated HGC-27 cells was consistently reversed (Figure 5B&C&E; Supplementary files, Figure S12). Furthermore, we also found the expression of apoptosis protein markers (Bax) was significantly decreased, while the anti-apoptotic protein (Bcl-2) increased (Figure 5D; Supplementary files, Figure S13), which both indicated that mitochondrial fusion was partly rescued. The release of Cyto C could also reduce as permeability of mitochondrial outer membrane was rescued (Figure 5D; Supplementary files, Figure S13). Since Cyto C has been reported to be one of the main activators during the caspase-dependent cell death, caspase-pathway would be inhibited if Cyto C’s release was decreased. As expected, the expression of apoptosis protein markers (cleaved caspase-9/caspase-9, cleaved caspase-3/caspase-3) were significantly decreased (Figure 5F;
Supplementary files, Figure S14). Furthermore, cell viabilities, LDH leakage, cell proliferation and apoptotic levels were consistently reversed, when ROS was suppressed by NAC (Figure 5G&H&I&J). In all, these results indicated that HMON@CuS/Gd plus NIR might exert anti-proliferation effect through activating the ROS/mitochondria-damage/caspase pathway.

3.6 In vivo multi-mode imaging behaviors of HMON@CuS/Gd nanoparticles

Before moving forward to study in vivo tumor photo-therapy, in vivo biodistribution behaviors of such agent in HGC-27 tumor-bearing mice were studied. DIR, as a near-infrared lipophilic carbocyanine dye, has been used for many cell biology applications\[47, 48\]. DIR were first encapsulated into HMON@CuS/Gd NPs (HMON@CuS/Gd-DIR). Following that, tumor-bearing mice were treated with HMON@CuS/Gd-DIR via tail vein injections. After 6, 12 and 24 hours, the mice were imaged using a small animal in vivo fluorescence imaging system (DIGITAL FPRCISION MEDICINE Company, Beijing, China). The in vivo fluorescence images indicate that HMON@CuS/Gd could access the cancer region in 6 hours, then gradually enriched in the tumor site from 6h to 24h (Figure 6A; Supplementary files, Figure S15). As shown in Figure 6A, a significant fluorescence signal accumulated in the tumor in the HMON@CuS/Gd-treated mice and peaked at 24h, which provided an optimal therapeutic time window for subsequent therapy in vivo. Meanwhile, tumor-bearing mice were sacrificed 24h post injection, and major organs were collected for fluorescence imaging. Ex vivo imaging also showed that HMON@CuS/Gd NPs were mainly accumulated in the tumor region (Figure 6B), which further confirming that their passive tumor-targeting abilities through enhanced permeability and retention (ERP) effect\[49, 50\]. Moreover, to further demonstrate the enhancement of MRI, HGC-27 tumor-bearing mice were also detected using a 3.0 T MAGNETOM Skyra MRI scanner, as it has been verified that HMON@CuS/Gd could be used as MR T1 contrast agent in vitro. HMON@CuS/Gd solution (6 mg kg\(^{-1}\)) was tail-intravenous injected, and then MRI images of the tumor were obtained after 24h. Figure 6C&D displayed that HMON@CuS/Gd could significantly enhanced T1-weighted signal after tail-intravenous administered, and these results not only highlighted the potential of HMON@CuS/Gd for MRI, but also again confirmed 24h as an optimal therapeutic time window for subsequent therapy in vivo.
Subsequently, the IRT imaging abilities of HMON@CuS/Gd in vivo were further investigated. HGC-27 tumors on mice that were exposed to NIR irradiation (0.8W/cm², 8mins), after tail-intravenous injected with HMON@CuS/Gd for 24 hours. As shown in Figure 6E&F, the tumor temperature of tumors increased from ~36 °C to ~44 °C within 3 minutes, while maintained at 43°C~45 °C in the next 5 minutes. This temperature was much greater than that (36 °C) experienced by mice administered saline plus NIR irradiation (0.8W/cm², 8mins), indicating that HMON@CuS/Gd did exhibit mild PTT effect (43-45 °C) under NIR irradiation (under 0.8 W/cm²), which would be much more attractive for clinical photo-therapeutic treatment.

Development of multifunctional nanoplatforms integrating both diagnostics and treatment functions for cancer nano-theranostics have attracted widespread research interest in nanobiotechnology. However, it is still worth to construct theranostic nano-systems with multi-modal imaging to guide therapy. Our results revealed that HMON@CuS/Gd did exhibit good fluorescence imaging, MRI imaging and infrared thermal imaging capacities. Furthermore, HMON@CuS/Gd NPs could selectively cause photo-therapy at cancer region, guided by fluorescence/MRI/thermal imaging. Taken together, HMON@CuS/Gd NPs might be a promising treatment for solid tumors with precise photo-therapeutic efficiency.

3.7 In vivo photo-therapeutic treatments of HMON@CuS/Gd nanoparticles in gastric cancer

To further analyze the antitumor effects of HMON@CuS/Gd NPs in vivo, we constructed tumor-bearing mice. Then, we randomly divided these mice into four groups, treating them with saline (negative control), saline plus NIR irradiation, HMON@CuS/Gd and HMON@CuS/Gd plus NIR irradiation. Fourteen-days’ post-treatment, we found that the relative tumor volume showed no significant difference between the saline group and saline plus NIR group, which meant that NIR itself could not inhibit tumor growth (Figure 7A&B&C&D). Furthermore, inhibited tumor growth rate in the HMON@CuS/Gd plus NIR irradiation group was approximately 80% compared to control group, while free HMON@CuS/Gd induced no significant changes (Figure 7A&B&C&D). We also observed the body-weight-change in these four groups, while no body-weight-loss was found (Figure 7E). The blood
serum samples were sent for the biochemical analysis of clinically relevant indicators (aspartate aminotransferase and alanine aminotransferase) for the liver and (blood urea nitrogen and creatinine) for the kidneys\textsuperscript{[44]}. No significant differences were observed in free NIR, free HMON@CuS/Gd and HMON@CuS/Gd plus NIR groups, compared to saline control groups, indicating that no damage happened in livers or kidneys (Figure 7F). Therefore, these results indicated that the photo-thermal therapy induced by HMON@CuS/Gd NPs could efficiently kill tumor cells with less side effect, indicating HMON@CuS/Gd NPs have a promising application for GC treatment.

The isolated issues were further sent for histological detection, while H&E staining (Figure 7G) further confirmed the collected specimen were tumors. TUNEL termed as “Terminal deoxynucleotidyl transferase dUTP nick end labeling”, which is a classic marker to detect DNA fragmentation in apoptotic tumor cells\textsuperscript{[53]}. Interestingly, we found that expression of TUNEL was upregulated in HMON@CuS/Gd plus NIR group, while no evident changes were found in other groups, compared with saline group (Figure 7G; Supplementary files, Figure S16). Consequently, the results of IHC consistently highlight the superiority of HMON@CuS/Gd plus NIR irradiation on anti-tumor proliferation, since this group showed highest expression of TUNEL.

**Conclusion**

In this work, we successfully constructed biocompatible and biodegradable Gd doped HMON decorated by CuS NPs (called HMON@CuS/Gd). The as-prepared NPs exhibited high photo-thermal conversion efficiency (82.4 %) and ROS generation ability. Differently from the reported HMON@CuS NPs, it was found that hyperthermia might not be the key factor of the cell apoptosis while ROS induced by PDT seems playing a more important role. PDT induced ROS would attack MTPs, promote mitoROS production and finally induced mitochondrial fusion. Meanwhile, mitochondrial damage again changed anti/pro-apoptotic proteins, opened mPTP, released Cyto C into cytosol, and finally activated caspase-9/caspase-3-depended cell apoptosis pathway. *In vivo* data showed that HMON@CuS/Gd could serve as a nanoplatfrom for fluorescence/ MRI/IRT triple modal imaging guided photo-therapy at cancer region, inhibit the growth of GC cells without evident systemic toxicity. Taken together, HMON@CuS/Gd could serve as a promising multifunctional nanotheranostic platform through inducing
mitochondrial fusion on gastric cancer.

Declarations

Acknowledgements

This work was supported by grants from National Natural Science Foundation of China (81601550; 81971746), China Postdoctoral Science Foundation (2019M662977; 2019M662986), Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation (pdjh2020a0106, pdjh2020a0109, pdjh2020a0108), Guangzhou City Science and Technology Project-Zhujiang Technology New Star Project (20160521606488), Natural Science Foundation of Guangdong Province (2017A030306023), Science and Technology Project of Guangdong Province (2018B090944002) and Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (2017J006),

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Consent for publication

Not applicable.

Contributions

WG, ZC, JC, XF, BZ, WH and YH carried out most of the experiments and wrote this paper. YY, HH, YL, GS, YL and CP participated in this project. YL, GL, BZ, WH and YH proposed the idea and supported the project. All authors read and approved the final manuscript.

Disclosure

The authors declare no competing financial interest.

References

1. Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Hu Y, Liu H, Zheng C, Li P, Xie J, Liu F, Li Z, Zhao G, Yang K, Liu C, Li H, Chen P, Ji J, Li G. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. *Jama* 2019; 321(20): 1983-1992
Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2016; 34(12): 1350-1357 [PMID: 26903580 DOI: 10.1200/jco.2015.63.7215]

Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. *Cancer letters* 2017; 387: 95-105 [PMID: 27037062 DOI: 10.1016/j.canlet.2016.03.042]

Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. *Curr Biol* 2014; 24(10): R453-R462 [PMID: 24845678 DOI: 10.1016/j.cub.2014.03.034]

Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. *Pharmacol Rev* 2002; 54(1): 101-127 [PMID: 11870261 DOI: 10.1124/pr.54.1.101]

Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? *Trends Cell Biol* 2008; 18(4): 165-173 [PMID: 18296052 DOI: 10.1016/j.tcb.2008.01.006]

Jin T, Wang C, Tian Y, Dai C, Zhu Y, Xu F. Mitochondrial metabolic reprogramming: An important player in liver cancer progression. *Cancer letters* 2020; 470: 197-203 [PMID: 31783085 DOI: 10.1016/j.canlet.2019.11.029]

Zong W-X, Rabinowitz JD, White E. Mitochondria and Cancer. *Molecular cell* 2016; 61(5): 667-676 [PMID: 26942671 DOI: 10.1016/j.molcel.2016.02.011]

Ahn CS, Metallo CM. Mitochondria as biosynthetic factories for cancer proliferation. *Cancer & metabolism* 2015; 3(1): 1-1 [PMID: 25621173 DOI: 10.1186/s40170-015-0128-2]

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip A-NA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong J-W, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin Y-H, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J,
Serrelli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. *Nature medicine* 2018; 24(7): 1036-1046 [PMID: 29892070 DOI: 10.1038/s41591-018-0052-4]

11 Cadenas S. Mitochondrial uncoupling, ROS generation and cardioprotection. *Biochim Biophys Acta Bioenerg* 2018; 1859(9): 940-950 [PMID: 29859845 DOI: 10.1016/j.bbabio.2018.05.019]

12 Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, Malech HL, Ledbetter JA, Elkon KB, Kaplan MJ. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. *Nature medicine* 2016; 22(2): 146-153 [PMID: 26779811 DOI: 10.1038/nm.4027]

13 Chang M, Wang M, Shu M, Zhao Y, Ding B, Huang S, Hou Z, Han G, Lin J. Enhanced photoconversion performance of NdVO(4)/Au nanocrystals for photothermal/photoacoustic imaging guided and near infrared light-triggered anticancer phototherapy. *Acta biomaterialia* 2019; 99: 295-306 [PMID: 31437636 DOI: 10.1016/j.actbio.2019.08.026]

14 Chang Y, Feng Y, Cheng Y, Zheng R, Wu X, Jian H, Zhang D, Tang Z, Wang Z, Hao J, Zhang H. Anisotropic Plasmonic Metal Heterostructures as Theranostic Nanosystems for Near Infrared Light-Activated Fluorescence Amplification and Phototherapy. *Adv Sci (Weinh)* 2019; 6(11): 1900158-1900158 [PMID: 31179221 DOI: 10.1002/advs.201900158]

15 Song Y, Shi Q, Zhu C, Luo Y, Lu Q, Li H, Ye R, Du D, Lin Y. Mitochondrial-targeted multifunctional mesoporous Au@Pt nanoparticles for dual-mode photodynamic and photothermal therapy of cancers. *Nanoscale* 2017; 9(41): 15813-15824 [PMID: 29018855 DOI: 10.1039/c7nr04881e]

16 Yang Z, Wang J, Liu S, Li X, Miao L, Yang B, Zhang C, He J, Ai S, Guan W. Defeating relapsed and refractory malignancies through a nano-enabled mitochondria-mediated respiratory inhibition and damage pathway. *Biomaterials* 2020; 229: 119580-119580 [PMID: 31707296 DOI: 10.1016/j.biomaterials.2019.119580]

17 Zhou Z, Song J, Nie L, Chen X. Reactive oxygen species generating systems meeting
challenges of photodynamic cancer therapy. *Chem Soc Rev* 2016; **45**(23): 6597-6626 [PMID: 27722328 DOI: 10.1039/c6cs00271d]

18 Oei AL, Kok HP, Oei SB, Horsman MR, Stalpers LJA, Franken NAP, Crezee J. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. *Advanced drug delivery reviews* 2020: S0169-0409X(0120)30005-30003 [PMID: 31982475 DOI: 10.1016/j.addr.2020.01.003]

19 Peng C, Liang Y, Chen Y, Qian X, Luo W, Chen S, Zhang S, Dan Q, Zhang L, Li M, Yuan M, Zhao B, Li Y. Hollow Mesoporous Tantalum Oxide Based Nanospheres for Triple Sensitization of Radiotherapy. *ACS applied materials & interfaces* 2020; **12**(5): 5520-5530 [PMID: 31891473 DOI: 10.1021/acsami.9b20053]

20 Wu J, Bremner DH, Niu S, Shi M, Wang H, Tang R, Zhu LM. Chemodrug-Gated Biodegradable Hollow Mesoporous Organosilica Nanotheranostics for Multimodal Imaging-Guided Low-Temperature Photothermal Therapy/Chemotherapy of Cancer. *ACS applied materials & interfaces* 2018; **10**(49): 42115-42126 [PMID: 30462492 DOI: 10.1021/acsami.8b16448]

21 Lu N, Fan W, Yi X, Wang S, Wang Z, Tian R, Jacobson O, Liu Y, Yung BC, Zhang G, Teng Z, Yang K, Zhang M, Niu G, Lu G, Chen X. Biodegradable Hollow Mesoporous Organosilica Nanotheranostics for Mild Hyperthermia-Induced Bubble-Enhanced Oxygen-Sensitized Radiotherapy. *ACS nano* 2018; **12**(2): 1580-1591 [PMID: 29384652 DOI: 10.1021/acsnano.7b08103]

22 Gu X, Qiu Y, Lin M, Cui K, Chen G, Chen Y, Fan C, Zhang Y, Xu L, Chen H, Wan JB, Lu W, Xiao Z. CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance. *Nano letters* 2019; **19**(5): 3344-3352 [PMID: 30974946 DOI: 10.1021/acs.nanolett.9b01065]

23 Chen W-H, Luo G-F, Lei Q, Hong S, Qiu W-X, Liu L-H, Cheng S-X, Zhang X-Z. Overcoming the Heat Endurance of Tumor Cells by Interfering with the Anaerobic Glycolysis Metabolism for Improved Photothermal Therapy. *ACS nano* 2017; **11**(2): 1419-1431 [PMID: 28107631 DOI: 10.1021/acsnano.6b06658]

24 Yoo D, Jeong H, Noh S-H, Lee J-H, Cheon J. Magnetically triggered dual functional nanoparticles for resistance-free apoptotic hyperthermia. *Angewandte Chemie (International ed in
Xing X, Zhang B, Wang X, Liu F, Shi D, Cheng Y. An "imaging-biopsy" strategy for colorectal tumor reconfirmation by multipurpose paramagnetic quantum dots. *Biomaterials* 2015; **48**: 16-25 [PMID: 25701028 DOI: 10.1016/j.biomaterials.2015.01.011]

Yu J, Diao X, Zhang X, Chen X, Hao X, Li W, Zhang X, Lee C-S. Water-dispersible, pH-stable and highly-luminescent organic dye nanoparticles with amplified emissions for in vitro and in vivo bioimaging. *Small (Weinheim an der Bergstrasse, Germany)* 2014; **10**(6): 1125-1132 [PMID: 24318966 DOI: 10.1002/smll.201302230]

Wang Z, Zhang F, Shao D, Chang Z, Wang L, Hu H, Zheng X, Li X, Chen F, Tu Z, Li M, Sun W, Chen L, Dong W-F. Janus Nanobullets Combine Photodynamic Therapy and Magnetic Hyperthermia to Potentiate Synergetic Anti-Metastatic Immunotherapy. *Adv Sci (Weinheim)* 2019; **6**(22): 1901690-1901690 [PMID: 31763151 DOI: 10.1002/advs.201901690]

Zhang X, Xi Z, Machuki JOa, Luo J, Yang D, Li J, Cai W, Yang Y, Zhang L, Tian J, Guo K, Yu Y, Gao F. Gold Cube-in-Cube Based Oxygen Nanogenerator: A Theranostic Nanoplatform for Modulating Tumor Microenvironment for Precise Chemo-Phototherapy and Multimodal Imaging. *ACS nano* 2019; **13**(5): 5306-5325 [PMID: 31018094 DOI: 10.1021/acsnano.8b09786]

Wang FH, Bae K, Huang ZW, Xue JM. Two-photon graphene quantum dot modified Gd(2)O(3) nanocomposites as a dual-mode MRI contrast agent and cell labelling agent. *Nanoscale* 2018; **10**(12): 5642-5649 [PMID: 29528344 DOI: 10.1039/c7nr08068a]

Shen Z, Fan W, Yang Z, Liu Y, Bregadze VI, Mandal SK, Yung BC, Lin L, Liu T, Tang W, Shan L, Liu Y, Zhu S, Wang S, Yang W, Bryant LH, Nguyen DT, Wu A, Chen X. Exceedingly Small Gadolinium Oxide Nanoparticles with Remarkable Relaxivities for Magnetic Resonance Imaging of Tumors. *Small (Weinheim an der Bergstrasse, Germany)* 2019; **15**(41): e1903422-e1903422 [PMID: 31448577 DOI: 10.1002/smll.201903422]

Chen W, Wang X, Zhao B, Zhang R, Xie Z, He Y, Chen A, Xie X, Yao K, Zhong M, Yuan M. CuS-MnS(2) nano-flowers for magnetic resonance imaging guided photothermal/photodynamic therapy of ovarian cancer through necroptosis. *Nanoscale* 2019; **11**(27): 12983-12989 [PMID: 31264665 DOI: ...
32 You Q, Sun Q, Wang J, Tan X, Pang X, Liu L, Yu M, Tan F, Li N. A single-light triggered and dual-imaging guided multifunctional platform for combined photothermal and photodynamic therapy based on TD-controlled and ICG-loaded CuS@mSiO(2). *Nanoscale* 2017; 9(11): 3784-3796 [PMID: 28067380 DOI: 10.1039/c6nr09042g]

33 Li W, Peng J, Tan L, Wu J, Shi K, Qu Y, Wei X, Qian Z. Mild photothermal therapy/photodynamic therapy/chemotherapy of breast cancer by Lyp-1 modified Docetaxel/IR820 Co-loaded micelles. *Biomaterials* 2016; 106: 119-133 [PMID: 27561883 DOI: 10.1016/j.biomaterials.2016.08.016]

34 Jin R-M, Yang J, Ding P, Li C, Zhang B, Chen W, Zhao Y-D, Cao Y, Liu B. Antitumor Immunity triggered by photothermal therapy and photodynamic therapy of a 2D MoS2 nanosheet-incorporated injectable polypeptide-engineered hydrogel combinated with chemotherapy for 4T1 breast tumor therapy. *Nanotechnology* 2020: 10.1088/1361-6528/ab1072b1089 [PMID: 32018232 DOI: 10.1088/1361-6528/ab72b9]

35 Bradford JA, Clarke ST. Dual-pulse labeling using 5-ethynyl-2’-deoxyuridine (EdU) and 5-bromo-2’-deoxyuridine (BrdU) in flow cytometry. *Curr Protoc Cytom* 2011; Chapter 7: 7.38 [PMID: 21207361 DOI: 10.1002/0471142956.cy0738s55]

36 Hu Y, Huang L, Shen M, Liu Y, Liu G, Wu Y, Ding F, Ma K, Wang W, Zhang Y, Shao Z, Cai X, Xiong L. Pioglitazone Protects Compression-Mediated Apoptosis in Nucleus Pulposus Mesenchymal Stem Cells by Suppressing Oxidative Stress. *Oxid Med Cell Longev* 2019; 2019: 4764071-4764071 [PMID: 31885796 DOI: 10.1155/2019/4764071]

37 Bhandary B, Marahatta A, Kim HR, Chae HJ. An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. *International journal of molecular sciences* 2012; 14(1): 434-456 [PMID: 23263672 PMCID: PMC3565273 DOI: 10.3390/ijms14010434]

38 Loreto C, La Rocca G, Anzalone R, Caltabiano R, Vespasiani G, Castorina S, Ralph DJ, Cellek S, Musumeci G, Giunta S, Djinovic R, Basic D, Sansalone S. The role of intrinsic pathway in apoptosis activation and progression in Peyronie's disease. *BioMed research international* 2014; 2014: 616149
[PMID: 25197653 PMCID: PMC4147380 DOI: 10.1155/2014/616149]

Zhang W, Hu X, Shen Q, Xing D. Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy. *Nature communications* 2019; **10**(1): 1704-1704 [PMID: 30979885 DOI: 10.1038/s41467-019-09566-3]

Deng L, Guo W, Li G, Hu Y, Zhang L-M. Hydrophobic IR780 loaded sericin nanomicelles for phototherapy with enhanced antitumor efficiency. *International journal of pharmaceutics* 2019; **566**: 549-556 [PMID: 31158452 DOI: 10.1016/j.ijpharm.2019.05.075]

Oparka M, Walczak J, Malinska D, van Oppen LMPE, Szczepanowska J, Koopman WJH, Wieckowski MR. Quantifying ROS levels using CM-H(2)DCFDA and HyPer. *Methods (San Diego, Calif)* 2016; **109**: 3-11 [PMID: 27302663 DOI: 10.1016/j.ymeth.2016.06.008]

Puleston D. Detection of Mitochondrial Mass, Damage, and Reactive Oxygen Species by Flow Cytometry. *Cold Spring Harb Protoc* 2015; **2015**(9): pdb.prot086298-pdb.prot086298 [PMID: 26330624 DOI: 10.1101/pdb.prot086298]

McArthur K, Whitehead LW, Heddleston JM, Li L, Padman BS, Oorschot V, Geoghegan ND, Chappaz S, Davidson S, San Chin H, Lane RM, Dramicanin M, Saunders TL, Sugiana C, Lessene R, Osellame LD, Chew T-L, Dewson G, Lazarou M, Ramm G, Lessene G, Ryan MT, Rogers KL, van Delft MF, Kile BT. BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. *Science (New York, NY)* 2018; **359**(6378): eaa0647 [PMID: 29472455 DOI: 10.1126/science.aao6047]

Guo W, Deng L, Chen Z, Chen Z, Yu J, Liu H, Li T, Lin T, Chen H, Zhao M, Zhang L, Li G, Hu Y. Vitamin B12-conjugated sericin micelles for targeting CD320-overexpressed gastric cancer and reversing drug resistance. *Nanomedicine (London, England)* 2019; **14**(3): 353-370 [PMID: 30328369 DOI: 10.2217/nnm-2018-0321]

Guo W, Deng L, Yu J, Chen Z, Woo Y, Liu H, Li T, Lin T, Chen H, Zhao M, Zhang L, Li G, Hu Y. Sericin nanomicelles with enhanced cellular uptake and pH-triggered release of doxorubicin reverse cancer drug resistance. *Drug delivery* 2018; **25**(1): 1103-1116 [PMID: 29742945 PMCID: PMC6058513 DOI: 10.1080/10717544.2018.1469686]
Saxena S, Vekaria H, Sullivan PG, Seifert AW. Connective tissue fibroblasts from highly regenerative mammals are refractory to ROS-induced cellular senescence. *Nature communications* 2019; **10**(1): 4400-4400 [PMID: 31562333 DOI: 10.1038/s41467-019-12398-w]

Li Y, Lin J, Ma J, Song L, Lin H, Tang B, Chen D, Su G, Ye S, Zhu X, Luo F, Hou Z. Methotrexate-Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy. *ACS applied materials & interfaces* 2017; **9**(40): 34650-34665 [PMID: 28920426 DOI: 10.1021/acsami.7b10027]

Griffin JI, Benchimol MJ, Simberg D. Longitudinal monitoring of skin accumulation of nanocarriers and biologicals with fiber optic near infrared fluorescence spectroscopy (FONIRS). *Journal of controlled release : official journal of the Controlled Release Society* 2017; **247**: 167-174 [PMID: 28069552 DOI: 10.1016/j.jconrel.2017.01.006]

Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. *Advanced drug delivery reviews* 2011; **63**(3): 131-135 [PMID: 20304019 DOI: 10.1016/j.addr.2010.03.011]

Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. *Cancer research* 2013; **73**(8): 2412-2417 [PMID: 23423979 DOI: 10.1158/0008-5472.CAN-12-4561]

Lyu M, Zhu D, Duo Y, Li Y, Quan H. Bimetallic nanodots for tri-modal CT/MRI/PA imaging and hypoxia-resistant thermoradiotherapy in the NIR-II biological windows. *Biomaterials* 2020; **233**: 119656-119656 [PMID: 31864762 DOI: 10.1016/j.biomaterials.2019.119656]

Wang Y, Zhang F, Lin H, Qu F. Biodegradable Hollow MoSe(2)/Fe(3)O(4) Nanospheres as the Photodynamic Therapy-Enhanced Agent for Multimode CT/MR/IR Imaging and Synergistic Antitumor Therapy. *ACS applied materials & interfaces* 2019; **11**(47): 43964-43975 [PMID: 31664811 DOI: 10.1021/acsami.9b17237]

Majtnerova P, Rousar T. An overview of apoptosis assays detecting DNA fragmentation. *Molecular biology reports* 2018; **45**(5): 1469-1478 [PMID: 30022463 DOI: 10.1007/s11033-018-4258-9]
Figures
Figure 1

(A) Elemental mappings of Cu and Gd elements for HMON@CuS/Gd NPs. (B) TEM images of biodegradable HMON@CuS/Gd NPs immersed in 10 mM GSH aqueous solution for 7 days and 14 days. (C&D) T1-weighted MR images of HMON@CuS/Gd at various concentrations (left) and the relative MR signal intensities (right). (E&F) The temperature increase curve induced by different concentrations of HMON@CuS/Gd aqueous solutions and PBS under NIR irradiation (0.8 W/cm², 5 mins). (G) Photo-thermal stability of HMON@CuS/Gd NPs under NIR laser irradiation (0.8 W/cm², 5 mins). (H) The production of singlet oxygen by the HMON@CuS/Gd NPs with or without NIR irradiation (0.8 W/cm², 5 mins). Data are shown as mean ± SD, n = 3.
(A) Cell viabilities of HGC-27 cells after treated with single HMON@CuS/Gd, HMON@CuS/Gd plus NIR and HMON@CuS/Gd plus NIR on ice, using CCK-8 assay. (B) LDH leakage of HGC-27 cells after treated with single HMON@CuS/Gd, HMON@CuS/Gd plus NIR and HMON@CuS/Gd plus NIR on ice, using LDH assay. (C) CCK-8 assay of HGC-27 cells after treated with single HMON@CuS/Gd, HMON@CuS/Gd plus NIR, HMON@CuS/Gd plus NIR on ice or HMON@CuS/Gd plus external heating. (D) LDH leakage assay of HGC-27 cells after treated with single HMON@CuS/Gd, HMON@CuS/Gd plus NIR, HMON@CuS/Gd plus NIR on ice or HMON@CuS/Gd plus external heating. (E) The CCK-8 assay of GES-1 cells after incubation with HMON@CuS/Gd NPs for 24 hours. (F) The confocal laser scanning microscopy (CLSM) images of RAW264.7 murine macrophage-like cells after incubation with HMON@CuS/Gd for 24 hours. Scale bar: 50 μm. Data are shown as mean ± SD, n = 3. * indicates P < 0.05, ***
indicates $P < 0.001$.

Figure 3

(A) Flow cytometry images of HGC-27 cells treated with HMON@CuS/Gd for 1-4 h (left), and corresponding quantification of green mean fluorescence intensity of FITC inside cells (right). (B) CLSM images of HGC-27 cells treated with HMON@CuS/Gd for 1-4 h (left), and corresponding quantification of CLSM images using the green mean fluorescence intensity of FITC (right). (C) Cell apoptosis images of HGC-27 cells (left) and statistical graph of total apoptotic rates (right), after treated with or without near infrared (NIR) irradiation, in the presence of HMON@CuS/Gd nanoparticle. (D) EdU images of HGC-27 cells (left) and statistical graph of EdU-positive rates (right), after treated with or without near infrared (NIR) irradiation, in the presence of HMON@CuS/Gd nanoparticle. Data are shown as mean ± SD, n = 3. *** indicates $P < 0.001$. 


HGC-27 cells were treated with or without near infrared (NIR) irradiation, in the presence of HMON@CuS/Gd nanoparticle, while divided into four groups, including blank, HMON@CuS/Gd, sing NIR and HMON@CuS/Gd plus NIR treatments. (A) Transmission electron microscope (TEM) images of HGC-27 cells. (B) Mitochondrial transmembrane potentials (MTPs, left) and statistical graph of total MTPs (right) in HGC-27 cells, detected by flow cytometry. (C) Total ROS images of HGC-27 cells (left), and statistical graph of ROS content in HGC-27 cells (right), detected by flow cytometry. (D) MitoROS images of HGC-27 cells (left), and statistical graph of mitoROS content in HGC-27 cells (right), detected by flow cytometry. (E) Expressions of Cyto C, Bax, Bcl-2 and GAPDH proteins in HGC-27 cells, detected by western blotting. (F) Mitochondrial permeability transition pore images (mPTP), detected by fluorescent inverted microscope. Scale bar, 500 nm. (G) Expressions of
caspase-9, cleaved caspase-9, caspase-3, cleaved caspase-3, and GAPDH proteins in HGC-27 cells, detected by western blotting. Data are shown as mean ± SD, n = 3. *** indicates P < 0.001.

Figure 5

HGC-27 cells were treated with HMON@CuS/Gd plus NIR irradiation, with or without the addition of NAC. (A) Total ROS images of HGC-27 cells (left), and statistical graph of ROS
content in HGC-27 cells (right), detected by flow cytometry. (B) MTPs images of HGC-27 cells (left), and statistical graph of MTPs in HGC-27 cells (right), detected by flow cytometry. (C) MitoROS images of HGC-27 cells (left), and statistical graph of mitoROS content in HGC-27 cells (right), detected by flow cytometry. (D) Expressions of Cyto C, Bax, Bcl-2 and GAPDH proteins in HGC-27 cells, detected by western blotting. (E) MPTP images of HGC-27 cells, detected by fluorescence microscope. Scale bar, 500 nm. (F) Expressions of caspase-9, cleaved caspase-9, caspase-3, cleaved caspase-3, and GAPDH in HGC-27 cells, detected by western blotting. (G) Cell viabilities of HGC-27 cells, detected by CCK-8 assay. (H) LDH leakage of HGC-27 cells, detected by LDH assay. after treated with or without NAC, in the presence of HMON@CuS/Gd plus NIR treatment. (I) Cell apoptosis images of HGC-27 cells (left) and statistical graph of total apoptotic rates (right), detected by flow cytometry. (J) EdU images of HGC-27 cells (left) and statistical graph of EdU-positive rates (right). Scale bar, 500 nm. Data are shown as mean ± SD, n = 3. *** indicates P < 0.001.
In vivo multi-mode imaging behaviors of HMON@CuS/Gd NPs HGC-27 cells. (A) (A) In vivo fluorescence images of HGC-27 tumor bearing mice at 6, 12 and 24 hours after treatment with HMON@CuS/Gd. (B) Ex vivo Fluorescence image of major organs on mice. (C&D) In vivo MRI images of HGC-27 tumor bearing mice at 24 hours after treatment with HMON@CuS/Gd, and the statistical signal to noise ratio (SNR) at cancer region. (C&D) In vivo MRI images of HGC-27 tumor bearing mice at 24 hours after treatment with HMON@CuS/Gd (C; left), and the statistical signal to noise ratio (SNR) at cancer region (D; right). (E&F) In vivo IRT images
of HMON@CuS/Gd-treated HGC-27 tumor bearing mice at different time, ranging from 0 to 8 minutes with NIR irradiation (E; left), and the statistical temperature change at cancer region (F; right).

Figure 7

(A) Images of tumors derived from mice treated with saline, saline plus NIR, HMON@CuS/Gd and HMON@CuS/Gd plus NIR. (B&C) Tumor volumes and relative tumor volumes of HGC-27 tumors isolated from mice. (D) Tumor weights of HGC-27 tumors isolated from mice. (E)
Relative body weights of HGC-27 tumor-bearing mice. (F) Biochemical assay results of the sera collected from mice. AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; Cr, creatinine. (G) Histopathological analysis of tumors isolated from mice. Data are shown as mean ± SD, n = 4. Scale bar, 500 nm. *** indicates P < 0.001.

Figure 8

Scheme 1 The synthesis process, fluorescence (FL) / magnetic resonance imaging (MRI) / infrared thermal (IRT) trimodal imaging abilities and anti-tumor mechanism of HMON@CuS/Gd NPs in gastric cancer cells

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Supplementary materials-final.doc